Gland Pharma
Gland Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Gland Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Gland Pharma Ltd trades at a P/E of 36.32× and P/B of 3.60×.
Valuation
Profitability
Growth
Financial Health
Gland Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Gland Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
Gland Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹37,202 Cr and reported EPS of ₹62.28.
| Period | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue from Operations | 3,463 | 4,401 | 3,625 | 5,665 | 5,617 | 6,431 |
| Other Income | 135 | 224 | 240 | 170 | 214 | 316 |
| Total Income | 3,598 | 4,625 | 3,865 | 5,835 | 5,830 | 6,747 |
| Cost of Goods Sold (COGS) | 1,492 | 2,109 | 1,685 | 2,173 | 2,090 | 2,243 |
| Gross Profit | 1,971 | 2,291 | 1,939 | 3,492 | 3,526 | 4,188 |
| +Operating Expenses | 669 | 781 | 914 | 2,159 | 2,257 | 2,558 |
| EBITDA | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 |
| +Non-Operating Expenses | 102 | 116 | 98 | 371 | 420 | 433 |
| Profit Before Tax (PBT) | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 |
| +Tax Expense | 338 | 407 | 274 | 360 | 364 | 437 |
| Profit After Tax (PAT) | 997 | 1,212 | 781 | 772 | 699 | 1,027 |
| Earnings Per Share (EPS) | 60.94 | 73.75 | 47.42 | 46.90 | 42.40 | 62.35 |
| Diluted Shares Outstanding (Nos.) | 16 | 16 | 16 | 16 | 16 | 16 |
| +Additional Disclosures | 3,754 | 5,115 | 4,438 | 6,868 | 6,913 | 7,932 |
| Sales Growth % | — | 27.08 | -17.64 | 56.29 | -0.85 | 14.50 |
| YoY Sales Growth % | — | 27.08 | -17.64 | 56.29 | -0.85 | 14.50 |
| Material Cost % | 51 | 47 | 47 | 36 | 35 | 35 |
| Employee Cost % | 9 | 8 | 11 | 22 | 25 | 25 |
| Other Cost % | 10 | 10 | 14 | 16 | 15 | 14 |
| OPM % | 38 | 34 | 28 | 24 | 23 | 25 |
| Tax % | 25 | 25 | 26 | 32 | 34 | 30 |
| Profit Growth % | — | 21.54 | -35.54 | -1.10 | -9.57 | 47.07 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 1,203 | 1,400 | 878 | 989 | 891 | 1,206 |
Gland Pharma segment analysis: revenue and profit mix.
Disclosed business segments at Gland Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
Gland Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Gland Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Gland Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Gland Pharma Ltd's investment case rests on 6 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
Gland Pharma boasts a robust 24% operating profit margin (OPM), showcasing strong operational efficiency and high profitability. This is further supported by a substantial 49.9% quarterly profit growth, indicating strong market demand and a promising future.
The company maintains a conservative financial strategy with a low debt-to-equity ratio of 0.03, minimizing financial risk and providing flexibility for future investments and expansion opportunities. This strong financial position enhances its resilience to economic downturns.
Despite recent stock price fluctuations, Gland Pharma's high promoter holding of 51.8% demonstrates significant confidence in the company's long-term prospects from its key stakeholders, mitigating risks associated with potential hostile takeovers.
The robust 49.9% quarterly profit growth indicates strong market acceptance and potential for further expansion into new product lines or therapeutic areas, leveraging its operational efficiency.
With a low debt-to-equity ratio of 0.03, the company has significant financial flexibility to pursue strategic acquisitions or invest in R&D, driving future growth in the competitive pharma sector.
What can break it.
Gland Pharma's P/E ratio of 40.70 is notably higher than several peers like Cipla (23.71) and Dr Reddy's (18.09), suggesting a premium valuation. This requires strong sustained growth to justify the current price.
A recent decrease in promoter shareholding from 57.86% to 51.83% warrants monitoring. This trend requires further analysis to assess potential implications for company control and future strategic direction, impacting investor confidence.
The company's dividend yield of 0.95% is relatively low, which might be less appealing to income-focused investors. This suggests a preference for reinvesting profits over immediate shareholder returns.
Gland Pharma's Return on Equity (ROE) of 7.81% and Return on Capital Employed (ROCE) of 11.90% are significantly lower than many industry peers, indicating less efficient capital utilization.
The stock's current price of 1903.00 is below its 52-week high of 2131.00, indicating a recent downtrend. This suggests potential investor caution or market corrections, impacting short-term sentiment and requiring careful monitoring.
What would change my mind.
Trim if P/E re-rates above 47. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 3.24. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Gland Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Gland Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Gland Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Gland Pharma Ltd — derived from the live tape, not yesterday's close.
Gland Pharma Ltd last traded at ₹2,262.2 with an intraday range of ₹2,250–₹2,354 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹2262.20| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2535.47 | +273.27 | +12.08% |
| R3 | 2431.47 | +169.27 | +7.48% |
| R2 | 2392.73 | +130.53 | +5.77% |
| R1 | 2327.47 | +65.27 | +2.89% |
| PIVOT | 2288.73 | 26.53 | 1.17% |
| CURRENT | 2262.20 | — | — |
| S1 | 2015.47 | -246.73 | -10.91% |
| S2 | 2119.47 | -142.73 | -6.31% |
| S3 | 2184.73 | -77.47 | -3.42% |
| S4 | 2223.47 | -38.73 | -1.71% |
GLAND is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 2310 ~ 2350
Trading Inside opening range
Gland Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Gland Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Gland Pharma Ltd stood at 46.5% of traded volume, against a 20-day average of 46.9%.
Gland Pharma announcements: results, concalls, ratings, M&A.
Filings Gland Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Gland Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 147 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
Updates
Gland Pharma Limited has informed the Exchange regarding 'Allotment of 203259 Equity shares on exercise of Employee Stock Options'.
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
Gland Pharma Limited has informed the Exchange about Transcript
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Updates
Gland Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Gland Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
Gland Pharma insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| S SRINIVASA RAO | Insider | 26 Feb 2025 | buy | +2.8 K | ₹15.18 L | ₹542.00 |
Gland Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Gland Pharma has declared, sequenced by announce and record date.
Gland Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Gland Pharma Ltd: business, sector, key facts.
What Gland Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Gland Pharma Ltd operates in the Healthcare, listed as NSE: GLAND, BSE: 543245.
Gland Pharma Limited is a prominent pharmaceutical company specializing in the manufacturing and sale of injectable formulations. Its global reach extends to India, the United States, Europe, Canada, Australia, New Zealand, and other international markets, showcasing a significant international presence and distribution network. The company's business model centers around providing a diverse range of injectable medications to meet various therapeutic needs.
A core aspect of Gland Pharma's operations involves the research and development of active pharmaceutical ingredients (APIs). This includes the complex synthesis of molecules such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. This in-house capability allows for greater control over the quality and supply chain of their products, and signifies a commitment to innovation within the pharmaceutical sector.
The company's product portfolio caters to a wide spectrum of therapeutic areas. This includes anti-malarial, anti-infectives, anti-neoplastic, blood-related, cardiac, gastrointestinal, gynecological, hormonal, neuro/CNS, ophthalmological/otological, pain and analgesic, respiratory medications, and vitamins, minerals, and nutrient supplements. The breadth of therapeutic categories serviced indicates a commitment to addressing a variety of patient needs and healthcare challenges.
Beyond manufacturing and sales, Gland Pharma also offers contract development services. This suggests that the company not only produces its own injectable medications but also provides research and development support to other pharmaceutical entities. This additional revenue stream diversifies the company’s income and expands its role within the industry ecosystem.
Established in 1978 and headquartered in Hyderabad, India, Gland Pharma operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. This affiliation with a larger parent company provides financial backing and potentially access to broader resources and markets, contributing to the company's ongoing success and expansion.
Questions investors ask about Gland Pharma Ltd (GLAND).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Gland Pharma Ltd (GLAND)?
The current share price of Gland Pharma Ltd (GLAND) is ₹2,262.2. Today, the stock has declined by ₹44.30 (1.92%), trading in a range of ₹2,250 to ₹2,354. The stock opened at ₹2,311.5 with a trading volume of 6,95,609 shares.
02Is Gland Pharma Ltd stock a good investment for long-term?
Gland Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹37,202 crores, P/E ratio of 36.32, ROE of 10.53%, and ROCE of 11.90%. The dividend yield stands at 0.87%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Gland Pharma Ltd stock?
The 52-week high price of Gland Pharma Ltd (GLAND) is ₹0, while the 52-week low is ₹0. Currently trading at ₹2,262.2, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Gland Pharma Ltd stock at the current price?
Whether to buy Gland Pharma Ltd stock at ₹2,262.2 depends on multiple factors. The stock is currently trading with a P/E ratio of 36.32 and P/B ratio of 3.60. Today's performance shows a loss of 1.92%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Gland Pharma Ltd and when is the next dividend?
Gland Pharma Ltd offers a dividend yield of 0.87%, which means for every ₹100 invested at the current price of ₹2,262.2, you can expect to receive approximately ₹0.87 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Gland Pharma Ltd?
Gland Pharma Ltd's key financial metrics include: P/E Ratio: 36.32, P/B Ratio: 3.60, ROE: 10.53%, ROCE: 11.90%, Dividend Yield: 0.87%, EPS: ₹62.28, Book Value: ₹628.81, and Debt-to-Equity: 2.74. The company's market cap stands at ₹37,202 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Gland Pharma Ltd stock performing today in the market?
Gland Pharma Ltd stock opened at ₹2,311.5 and is currently trading at ₹2,262.2, showing a decline of ₹44.30 (1.92%). The intraday high is ₹2,354 and low is ₹2,250. The trading volume stands at 6,95,609 shares, indicating moderate market participation today.
08What is the P/E ratio of Gland Pharma Ltd and what does it indicate?
Gland Pharma Ltd has a Price-to-Earnings (P/E) ratio of 36.32, which means investors are willing to pay ₹36.32 for every ₹1 of earnings. With an EPS of ₹62.28, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Gland Pharma Ltd (GLAND) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy